The U.S. Food and Drug Administration (FDA) has given Actuate Therapeutics the green light to begin a clinical trial…
Articles by Marisa Horak, MS
In an early clinical trial testing the novel therapy Alpha DaRT for recurrent glioblastoma, the first three patients given the…
Liraltagene autoleucel (lira-cel), an experimental cell therapy in clinical development for recurrent ovarian cancer, has been tolerated well so far…
Cellcentric has raised $220 million in financing to support two clinical trials testing its potentially first-in-class oral therapy inobrodib…
A new genetic test for a group of blood cancers known as myeloid malignancies is expected to soon be…
An artificial intelligence (AI) tool can detect early-stage pancreatic cancer on standard medical scans up to three years before…
The first participant has been dosed in a clinical trial testing the experimental therapy GLIX1 in people with recurrent or…
May 8 is World Ovarian Cancer Day, a time when advocates around the world raise their voices to increase…
Gilead said it has completed its $7.8 billion acquisition of Arcellx, a deal the company hopes will allow…
The U.S. Food and Drug Administration (FDA) has named Terns Pharmaceuticals’ investigational oral agent TERN-701 a breakthrough therapy for…